The Fast Money traders take a look at today's biggest market movers.» Read More
CEO Linda McMahon explains why her company's a true intercontinental champion.
You figured the automakers would eventually scream "UNCLE!" I'm not sure it's a scream, but it's more than just a whisper. One thing is clear: the automakers are once again turning to 0 percent financing to spur sales that are stalling.
The chief executive of Bear Stearns told CNBC that despite recent market volatility, he is not aware of any imminent threat to the Wall Street investment bank's liquidity.
Everyone's favorite small-cap biotech put out a press release this morning, announcing that the Food and Drug Administration has agreed to change the Special Protocol Assessment (SPA) for Dendreon's Provenge.
The president and chief executive of the Walt Disney Company says his company is not recession-proof, but it is positioned well enough to avoid being badly hurt in an downturn.
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
Despite signs of an economic pullback in the United States, Freeport McMoran Copper & Gold is not worried about its business. Why? China is likely to pick up the slack.
U.S. bank Merrill Lynch will not need to return to the market again following the turbulence in credit markets that forced it to raise nearly $13 billion, its chief executive was quoted as saying.
This is quite possibly the last momentum stock around. Here's why the CEO thinks the growth will continue.
The risk will make you queasy, but the reward might be worth it.
First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.
The stunning pay packages of executives at financial groups hammered by the U.S. mortgage crisis came in for stinging criticism from Democratic lawmakers and investor advocates at a congressional hearing Friday.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
Countrywide Financial CEO Angelo Mozilo told a congressional panel Friday that he is "extremely concerned" that recent tightening of mortgage underwriting criteria has gone too far.
The heads of three companies implicated in the mortgage crisis have been asked to explain how they collectively received hundreds of millions of dollars in compensation while their companies were losing money.
The CEO of this dying newspaper company is a one-man black hole for shareholder value.
This waste management play is money in the bank so long as Romano is at the helm.
Surprise, surprise. Another CEO could get a massive payout despite his terrible performance.
There's an opportunity to make money, and Cramer doesn't want investors missing it.
I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...